Recent studies suggest that p53 dysfunction may cooperate with ATRX/DAXX loss of function to accelerate genomic rearrangements and tumor progression in ALT-positive contexts, highlighting a potential synthetic vulnerability that could be therapeutically exploited [40,52,53]. Here, TP53 is linked to neoplasm.